Thursday, October 15, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 28, 2026

United States AI in Healthcare Market Forecast Report and Company Analysis 2025-2033 Featuring AWS, General Vision, Google, Intel, Medtronic, Micron, Microsoft, Next IT, NVIDIA, Siemens Healthcare

View original at finance.yahoo.com
United States AI in Healthcare Market Forecast Report and Company Analysis 2025-2033 Featuring AWS, General Vision, Google, Intel, Medtronic, Micron, Microsoft, Next IT, NVIDIA, Siemens Healthcare Company Logo The United States AI in Healthcare Market is projected to soar from US$ 10.26 billion in 2025 to US$ 99.77 bil…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • California, Texas, New York, and Florida lead in AI healthcare adoption, bolstering U.S. AI healthcare innovation.

    80% confidence

  • Rapid digital transformation, growing demand for precision medicine, robust government support, and the need for affordable healthcare solutions are the main factors propelling the U.S. AI in healthcare market.

    80% confidence

  • The high cost of implementing AI technologies and the shortage of skilled professionals pose significant barriers to market growth.

    80% confidence

  • The United States AI in Healthcare Market is expected to reach US$ 99.77 billion by 2033 from US$ 10.26 billion in 2025, with a CAGR of 32.88% from 2025 to 2033.

    80% confidence

  • AI-powered precision medicine platforms are being deployed across oncology, neurology, and cardiology to identify molecular markers and optimize care delivery.

    80% confidence

  • One of the major challenges in the U.S. AI in Healthcare market is ensuring data privacy and compliance with complex regulations such as HIPAA and emerging state-specific laws.

    80% confidence

  • The FDA's support for AI-based medical devices and government programs encouraging healthcare digitization further accelerate industry growth.

    80% confidence

  • NLP advancements are accelerating AI adoption across the U.S. healthcare sector by transforming how unstructured clinical data is utilized.

    80% confidence

  • The United States is becoming a global leader in healthcare innovation as a result of the acceleration of AI integration brought about by rising healthcare costs and the expansion of big data availability.

    80% confidence

  • Many small and mid-sized hospitals struggle to afford AI technologies, leading to uneven adoption across regions.

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
United States AI in Healthcare Market Forecast Report and Company Analysis 2025-2033 Featuring AWS, General Vision, Google, Intel, Medtronic, Micron, Microsoft, Next IT, NVIDIA, Siemens Healthcare — Source | Via News | Via News